$3.36
5.33% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
CH1125843347
Symbol
SOPH

SOPHiA Genetics SA Stock price

$3.36
+0.09 2.75% 1M
-1.28 27.59% 6M
-1.35 28.66% YTD
-1.51 31.01% 1Y
-9.86 74.58% 3Y
-13.40 79.95% 5Y
-13.40 79.95% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
+0.17 5.33%
ISIN
CH1125843347
Symbol
SOPH

Key metrics

Market capitalization $219.66m
Enterprise Value $155.54m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.41
P/S ratio (TTM) P/S ratio 3.41
P/B ratio (TTM) P/B ratio 1.97
Revenue growth (TTM) Revenue growth 9.85%
Revenue (TTM) Revenue $64.49m
EBIT (operating result TTM) EBIT $-68.29m
Free Cash Flow (TTM) Free Cash Flow $-44.03m
Cash position $95.79m
EPS (TTM) EPS $-1.09
P/E forward negative
P/S forward 3.35
EV/Sales forward 2.37
Short interest 0.05%
Show more

Is SOPHiA Genetics SA a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

SOPHiA Genetics SA Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a SOPHiA Genetics SA forecast:

5x Buy
83%
1x Hold
17%

Analyst Opinions

6 Analysts have issued a SOPHiA Genetics SA forecast:

Buy
83%
Hold
17%

Financial data from SOPHiA Genetics SA

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
64 64
10% 10%
100%
- Direct Costs 21 21
15% 15%
32%
44 44
8% 8%
68%
- Selling and Administrative Expenses 69 69
3% 3%
107%
- Research and Development Expense 35 35
3% 3%
54%
-60 -60
6% 6%
-93%
- Depreciation and Amortization 8.29 8.29
5% 5%
13%
EBIT (Operating Income) EBIT -68 -68
5% 5%
-106%
Net Profit -71 -71
4% 4%
-111%

In millions USD.

Don't miss a Thing! We will send you all news about SOPHiA Genetics SA directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

SOPHiA Genetics SA Stock News

Neutral
PRNewsWire
about one month ago
Launch of new application enables global access to highly recognized solid tumor profiling assay BOSTON and ROLLE, Switzerland , Nov. 21, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology leader in data-driven medicine, announced the global launch of MSK-IMPACT® powered with SOPHiA DDM™ today from the Association for Molecular Pathology (AMP) Annual Meeti...
Neutral
Seeking Alpha
about 2 months ago
SOPHiA GENETICS SA (NASDAQ:SOPH ) Q3 2024 Earnings Conference Call November 5, 2024 8:00 AM ET Company Participants Kellen Sanger - Head of Strategy and Investor Relations Jurgi Camblong - Co-Founder and Chief Executive Officer George Cardoza - Incoming Chief Financial Officer Ross Muken - Executive Vice President, Chief Financial Officer & Chief Operating Officer Conference Call Participants D...
Neutral
PRNewsWire
about 2 months ago
BOSTON and ROLLE, Switzerland , Nov. 5, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today announced that Ross Muken, previously Chief Financial Officer ("CFO") and Chief Operating Officer ("COO"), has been promoted to company President, effective November 5, 2024. George Cardoza has been appointed as the company's new ...
More SOPHiA Genetics SA News

Company Profile

SOPHiA GENETICS SA is a healthcare technology company, which establishes the practice of data driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM Platform, a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The company was founded by Jurgi Camblong, Pierre Hutter and Lars Steinmetz in 2011 and is headquartered in Saint Sulpice, Switzerland.

Head office Switzerland
CEO Jurgi Camblong
Employees 449
Founded 2011
Website www.sophiagenetics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today